Background: Due to the lack of comprehensive evidence based on prospective studies, the
efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib …

Hair loss, or alopecia, is associated with several psychosocial and medical comorbidities,
and it remains an economic burden to individuals and the society. Alopecia is attributable to …

Background Alopecia areata is an autoimmune condition characterized by rapid hair loss in
the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral …

Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T‐cell (Th2)‐immune response in AA …

Alopecia areata (AA) is a chronic, immune‐mediated disease characterized by acute or
chronic non‐scarring hair loss, with a heterogeneity in clinical manifestations ranging from …

Alopecia areata is a type of non-scarring hair loss. The dysregulation of numerous systemic
Th1 (IL-2, IFN-γ, TNF, IL-12, and IL-18), Th2 (IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17E, IL-31 …

Alopecia areata is an autoimmune hair loss disease that is non-scarring and is
characterized by chronic inflammation at the hair follicle level. Clinically, patients' …

Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. As a
clinically heterogeneous disease, various classification systems have evolved for defining its …

Introduction Alopecia areata (AA) is an autoimmune disorder causing sudden, non-scarring
hair loss. There are currently no drugs approved for AA treatment. This study assessed …

Background Several studies have linked various chronic inflammatory skin diseases
(CISDs) with inflammatory bowel disease (IBD) in a range of data sources with mixed …